Revvity, Inc. (RVTY) SEC Filings & Earnings Calls

Tariff uncertainty and potential supply chain disruption

“The timing and amount of additional recoveries remain uncertain and will depend on the scope and timing of court or administrative developments and completion of applicable administrative steps.” · word for word

Restructuring execution risk

“Restructuring and other costs in the second quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations.” · word for word

Divestiture of China IDX subject to regulatory approvals and closing conditions; expected close by end of 2027.

“The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals.” · word for word

Tariff refunds ($16M) boosted earnings; sustainability uncertain.

“GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related refunds)” · word for word

Tariff impact on margins

“Tariffs enacted and currently in effect increased our cost of revenue by approximately $8 million for the three months ended April 5, 2026. Through proactive mitigation efforts, the net impact on gross margin was approximately $6 million for the three months ended April 5, 2026.” · word for word

Restructuring execution risk

“Restructuring and other costs increased and was $10.7 million for the three months ended April 5, 2026, as compared to $3.2 million for the three months ended March 30, 2025. In the first quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of our workforce.” · word for word

Government funding uncertainty

“Recently announced and proposed changes in U.S. funding and regulations have created a more cautious spending environment for our customers and could cause them to become more conservative with both instrumentation and consumable purchases due to funding and regulatory uncertainty.”

Divestiture execution risk: China IDX sale subject to regulatory approvals and closing conditions.

“Sale expected to close in 2027; subject to adjustments and regulatory approvals.”

Margin compression: Adjusted operating margin declined 200 bps YoY due to mix and investment.

“Adjusted operating profit margin 23.6% vs 25.6% YoY.”

China Diagnostics Headwinds

“The Diagnostics segment faced significant headwinds in China, with sales declining due to changes in hospital lab reimbursement policies (specifically, Diagnosis-Related Groups or DRGs). Hospitals shifted from Revvity's higher-value multiplex tests to lower-priced alternatives, resulting in a meaningful pullback in Immunodiagnostics business.” · word for word

Academic/Government Segment Weakness

“The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year.” · word for word

Litigation Liability

“Revvity Health Sciences is facing a lawsuit from more than two dozen marijuana testing laboratories seeking $1 billion in damages. The suit accuses Revvity of a 'knowingly and intentionally deceptive marketing and sales campaign' to sell equipment that was not designed to test cannabis effectively.” · word for word

Tariff exposure

“Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market.” · word for word

Goodwill impairment risk

“The Life Sciences Solutions reporting unit, which had a goodwill balance of $4.5 billion at December 28, 2025, had a fair value that exceeded its carrying value by more than 10% but less than 20% as of the November 3, 2025 impairment testing date.” · word for word

Debt service obligations

“Our debt level and related debt service obligations could have negative consequences, including requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt” · word for word

Margin pressure: GAAP and adjusted operating margins declined year-over-year in both Q4 and full year, indicating cost or mix headwinds.

“GAAP operating profit margin from continuing operations was 14.5% as a percentage of revenue, as compared to 16.3% in the same period a year ago. Adjusted operating profit margin was 29.7% as a percentage of revenue, as compared to 30.3% in the same period a year ago.” · word for word

Life Sciences organic growth flat in Q4, suggesting potential end-market softness or competitive pressure.

“Life Sciences: Revenue increased 2% and organic revenue was flat as compared to the same period a year ago.”

Preliminary results subject to final adjustments.

“preliminary financial results are based on current expectations and may be adjusted”

Tariff cost impact

“We now estimate that pursuant to the tariffs recently enacted and currently in effect, our cost of revenue for the current fiscal year could increase by approximately $25 million.” · word for word

Gross margin pressure

“gross margin of 266 basis points to 53.6% for the three months ended September 28, 2025, from 56.3% for the three months ended September 29, 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift.” · word for word

Foreign exchange headwind

“unfavorable changes in foreign exchange rates” · word for word

Customer spending caution due to regulatory uncertainty

“Recently announced and proposed changes in U.S. funding and regulation has created a more cautious spending environment for our customers and could cause them to become more conservative with both instrumentation and consumable purchases due to funding and regulatory uncertainty.”

Margin compression due to higher costs and investments.

“GAAP operating margin declined from 14.3% to 11.7%; adjusted operating margin declined from 28.3% to 26.1%.”

Tariff and trade policy risks.

“Risk factors include recently implemented and recently threatened tariff increases.”